顺序响应的纳米-PROTACs用于精确的细胞内传递和增强降解疗效在结肠直肠癌治疗
Liuqing Yang1, Ye Yang1, Jing Zhang1
1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 100191, Beijing, China.
Signal transduction and targeted therapy
|October 17, 2024
概括
聚合物纳米粒子增强了用于结直肠癌治疗的PROTAC输送. 这些纳米粒子改善瘤透和细胞吸收,导致有效的蛋白质降解和协同抗癌效应,当与免疫检查点抑制剂相结合时.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 在瘤学瘤学.
背景情况:
- 蛋白质溶解向基因组 (PROTACs) 显示出治疗前景,但在组织透和细胞内化方面面临挑战.
- 结肠直肠癌 (CRC) 往往耐受常规治疗,包括免疫检查点封锁.
研究的目的:
- 设计pH/cathepsin B顺序响应纳米颗粒 (PSRNs) 来增强针对循环素依赖激酶4和6 (CDK4/6) 的PROTACs的细胞内传递.
- 在结直肠癌模型中评估PSRNs的疗效及其与免疫检查点抑制剂的组合.
主要方法:
- 开发具有pH和酶敏感性的聚合物PROTAC结合纳米粒子 (PSRNs).
- 在实验室和体内对纳米粒子积累,透,细胞吸收和PROTAC释放在结直肠癌模型中的评估.
- 评估CDK4/6降解,PD-L1表达,调节T细胞增殖和与α-PD-1疗法结合的抗瘤疗效.
主要成果:
- 在酸性瘤微环境中,PSRNs (40 nm) 在瘤中积累并解离成unimers (<10 nm),增强透和细胞吸收.
- CDK4/6-降解PROTACs的细胞内释放是由甲素B裂变引发的,导致体和体内增强的蛋白降解.
- 与α-PD-1的联合治疗显著改善了CT26瘤模型中的抗瘤结果,与PD-L1上调和抑制调节性T细胞增殖相关.
结论:
- 精确的PROTACs细胞内输送对于提高治疗疗效至关重要.
- 在结直肠癌中,PSRN提供了一种有希望的有针对性的联合治疗策略,通过改善PROTAC的输送和增强免疫检查点阻塞的有效性来改善结直肠癌.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


